市場調查報告書
商品編碼
921924
全球傷口護理用生物製劑市場:成長,趨勢,及預測(2020年~2025年)Wound Care Biologics Market - Growth, Trends, and Forecasts (2022 - 2027) |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
全球傷口護理用生物製劑市場,由於燒傷的負傷增加的負擔,糖尿病足部潰傷增加的負擔,及傷口護理相關政府的配合措施等要素而促進成長。根據國際糖尿病聯盟,2019年,世界中約有420萬人因糖尿病死亡。慢性創傷,尤其是腳潰瘍的發生率在糖尿病患者之間增加,因此導致傷口護理用生物製劑產品的使用增加。因此,針對更佳治療選項開發的焦點擴大,和疾病的大的負擔,帶動該市場。但,治療費用高,可能抑制市場成長。
本報告提供全球傷口護理用生物製劑市場的相關調查,市場機會和趨勢,成長及阻礙因素,各產品、創傷類型、終端用戶、地區的市場分析,競爭情形,主要企業的簡介等資訊。
Wound care biologics is gaining popularity for the treatment of wounds and burn injuries. Factors, such as growing burden of burn injuries, increasing burden of diabetic foot ulcers, and government initiatives regarding wound care treatment are driving the growth of the wound care biologics market.
Based on products, the market is segmented into biological skin substitutes and topical agents. The biological skin substitutes segment is expected to witness better growth due to their wide usage in the treatment of chronic wounds. These skin substitutes have an intact extracellular matrix for structural support. Biological skin substitutes are majorly recommended for burn injuries and treatment of chronic wounds, such as diabetic foot ulcers and venous leg ulcers. According to the International Diabetes Federation, in 2019, almost 463 million people (20-79 years) had diabetes, and by 2045, this is expected to rise to 700 million. Chronic wounds lead to complications, such as infection, ulceration, and insufficient blood supply. Hence, the increasing burden of diabetes and the growing adoption of these products are the major factors propelling the growth of the wound care biologics market.
North America is expected to dominate the wound care biologics market during the forecast years. This is mainly attributed to the growing diabetic population and the rising number of burn injury cases in the region. According to the American Burn Association, approximately 450,000 patients receive hospital and emergency room treatment for burns each year. Burn injury is one of the leading causes of unintentional death in the United States, which leads to increased adoption of wound care biologics by the hospitals or clinics. Hence, increased awareness, rapid adoption of new technologies, and increasing chronic wound cases are expected to positively impact market growth in this region.
The wound care biologics market is competitive and many of the global players are in the market. For instance, ACell Inc., Integra LifeSciences Corporation, Kerecis, Marine Polymer Technologies Inc., MiMedx Inc., Misonix, Inc., Molnlycke Health Care, Smith & Nephew PLC, and Wright Medical Group NV are providing these products across the world.